Washington State Life Science Investment Report – March

• Policy Blog
• 2026

Policy Blog – March 16, 2026 – Legislature Adjourns After Contentious Session Marked by Tax Debate and Budget Battles

The 2026 legislative session concluded Thursday evening at 8:24 PM, bringing to a close one of the most contentious sessions in recent years. What began in January as a debate over how to address a projected $2.3B budget shortfall quickly evolved into a broader fight over taxes and spending, culminating in the passage of the […]

• Policy Blog
• 2026

Policy Blog – March 9, 2026 – SBIR Reauthorization Clears US Senate, Legislature Enters Final Week of Session

The US Senate last week unanimously passed legislation to reauthorize the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, which provide critical early-stage funding for small Washington companies developing new technologies and therapies. The programs expired in October, but Congress is now moving to restore it. The House is also expected […]

• Policy Blog
• 2026

Policy Blog – March 2, 2026 – Final Weeks of Session: Budget Decisions, Taxes, and 340B in Focus

We are now in the two-week home stretch of the 2026 legislative session. All regular committee deadlines have passed, meaning most policy bills that have not already advanced are effectively done for the year, except for measures that impact state revenue or are deemed necessary to implement the budget (NTIB). With House and Senate budget […]

• Industry Reports
• 2026

Washington State Life Science Investment Report – January 2026